Early Stage Breast Cancer Treatments for Younger Medicare Beneficiaries with Different Disabilities. Health Services Research, 43(5p1), 1752-1767. PubMed doi:10.1111/j.1475-6773.2008.00853.xIezzoni LI, Ngo LH, Li D, et al. Early Stage Breast Cancer Treatments for Younger Medicare Beneficiaries...
EP: 16.Case Discussion 2: Systemic Therapy for ER+, PR+, HER2- Breast Cancer EP: 17.Treatment Advances in HR+ Breast Cancer Sara Hurvitz, MD: Andrew, every patient is different, but how do you approach a low-risk, early-stage hormone receptor-positive breast cancer versus high-risk, no...
Opposing results of the monarchE and PALLAS trials investigating the role of adjuvant treatment with the CDK4/6 inhibitors abemaciclib and palbociclib, respectively, in patients with hormone receptor-positive, HER2-negative early stage breast cancer have recently been presented. Herein, potential reasons...
New/alternative treatment approaches in the local management of patients with early stage breast cancer. Proc Am Soc Clin Oncol. 2002;296–303. Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast, carcinoma: Long-term results of a randomized ...
The cost–benefit ratio of adjuvant treatments needs to be better defined for this patient population. There is an urgent need for clinical trials in order to move from patient-profile to evidence-based medicine. 展开 关键词: breast cancer breast conserving therapy modified radical mastectomy ...
We uncover a few puzzles around switching treatments, genetic testing, fertility specialists, and mental health. Explore More Article Questions for Your Doctor Play an active role in your cancer care plan with these questions to ask your doctor about early-stage breast cancer diagnosis and treatment...
The use of high-dose-rate brachytherapy alone after lumpectomy in patients with early-stage breast cancer treated with breast-conserving therapy A. Vicini. The use of high-dose-rate brachytherapy alone after lumpectomy in patients with early-stage breast cancer treated with breast-conserving therapy...
The exciting part of it all is that there are a lot of new, great systemic treatments for patients. This has dramatically changed even just in the past year, honestly. We’ve seen approvals for new agents for early-stage breast cancer. To me, this is probably one of the biggest take...
Under St Gallen: A treatment was considered “Under St Gallen” if the woman did not receive the main St Gallen recommendation for her cancer (in spite of whether she received additional treatments included in the main recommendation or not). For example, a woman with breast cancer oestrogen-...
This review concerns the effects on vision and the eye of medications prescribed at three phases of treatment for women with early-stage breast cancer (BC): (1) adjuvant cytotoxic chemotherapy, (2) adjuvant endocrine therapy, and (3) symptomatic relief. The most common side effects of cytotoxic...